Alendronate Sodium NDC 68071-3340

NDC codes

FDA NDC Directory

Product NDC (as listed)68071-3340Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68071-3340Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68071-3340-4	68071334004	4 TABLET in 1 BOX (68071-3340-4)Marketed from Jul 21, 2017

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Alendronate Sodium
Generic name (nonproprietary): alendronate sodium
Active ingredients: Alendronate sodium — 70 mg/1
Dosage form: Tablet
Route: Oral
Labeler: NuCare Pharmaceuticals,Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 076768
Marketing start: Aug 4, 2008
Listing expires: Dec 31, 2027
Other FDA classes: Diphosphonates (Chemical structure)
Identifiers: Product ID 68071-3340_54f0bd6e-614e-f240-e063-6394a90a2a25SPL ID 54f0bd6e-614e-f240-e063-6394a90a2a25SPL set ID 54d6543d-4239-58b1-e054-00144ff88e88RxCUI 904431UNII 2UY4M2U3RAUPC 0368071334043
Pharmacologic class: Bisphosphonate

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468071334004 followed by a unit qualifier and the quantity

Package 68071-3340-04. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 23, 2026.

Indications (excerpt from the label)

Alendronate sodium is a bisphosphonate indicated for: Treatment and prevention of osteoporosis in postmenopausal women ( 1.1 , 1.2 ) Treatment to increase bone mass in men with osteoporosis ( 1.3 ) Treatment of glucocorticoid-induced osteoporosis ( 1.4 ) Treatment of Paget's disease of bone ( 1.5 ) Limitations of use: Optimal duration of use has not been determined. For patients at low- risk for fracture, consider drug discontinuation after 3 to 5 years of use. ( 1.6 ) 1.1 Treatment of Osteoporosis in Postmenopausal Women Alendronate sodium tablets, USP are indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, alendronate sodium tablets, USP increase b…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 076768

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 076768
Product	Strength	Form · route	Labeler	Product NDC
Alendronate Sodium	Alendronate sodium 35 mg/1	TabletOral	Cipla USA Inc.	69097-223
Alendronate Sodium	Alendronate sodium 70 mg/1	TabletOral	Cipla USA Inc.	69097-224
Alendronate Sodium	Alendronate sodium 70 mg/1	TabletOral	Preferred Pharmaceuticals Inc.	68788-7130
Alendronate Sodium	Alendronate sodium 70 mg/1	TabletOral	A-S Medication Solutions	50090-4692
Alendronate Sodium	Alendronate sodium 35 mg/1	TabletOral	REMEDYREPACK INC.	70518-1192
Alendronate Sodium	Alendronate sodium 35 mg/1	TabletOral	EXELAN PHARMACEUTICALS INC.	76282-681
Alendronate Sodium	Alendronate sodium 70 mg/1	TabletOral	EXELAN PHARMACEUTICALS INC.	76282-682
Alendronate Sodium	Alendronate sodium 70 mg/1	TabletOral	NuCare Pharmaceuticals, Inc.	68071-3771
Alendronate Sodium	Alendronate sodium 70 mg/1	TabletOral	REMEDYREPACK INC.	70518-0033